Newsletter Subscription

Enter Name and Email

03 October 2011 - Just published: Review of anatomical selectivity for Parkinson's Disease therapy

Although L-DOPA is the mainstay of pharmacotherapy of Parkinson's disease (PD), it is associated with serious shortcomings over long-term use, notably troublesome dyskinesias. Serotonin 5-HT2A antagonism and 5-HT1A agonism may provide a strategy to alleviate dyskinesia whilst maintaining benefit on motor symptoms. However, the multiple subpopulations of these receptors complicates understanding of their influence. The present review proposes that 5-HT2A and/or 5-HT1A receptors located in cortical regions should be preferentially targeted in order to achieve optimal anti-dyskinetic efficacy without impairing the motor-facilitating effects of L-DOPA.

Jonathan Brotchie's laboratory has extensive experience of testing anti-PD drugs in non-human primates and Adrian Newman-Tancredi has investigated the preferential targeting of 5-HT1A receptor subpopulations. For more information, Contact.

Huot P, Fox SH, Newman-Tancredi A, Brotchie JM.

J Pharmacol Exp Ther. 2011 Oct;339(1):2-8. Epub 2011 Jul 22.